Bright Minds Biosciences Inc. announced that the International Searching Authority reviewed its international patent application directed to phenethylamine compounds and issued a Written Opinion indicating that Bright Minds' core phenethylamine compounds of interest are novel and inventive over the searched prior art. Bright Minds recently filed an international patent application (assigned a filing number of PCT/CA2023/050003) directed at compounds that belong to the phenethylamine class of molecules, which the Company believes are potentially best in class compounds with an optimized short half-life, highly potent and extreme selectivity relative to other 5-HT(2A) agonists in development. Compounds from the Company's 5-HT(2A), and 5-HT(2 A) /5-HT(2C) programs are contained in this patent application, including its lead 5-HT (2A) agonist, BMB 202, as well as other backup and compounds of high interest from both programs. While the Written Opinion is non-binding, the Written Opinion is encouraging news and supports the view that Bright Minds has developed patentable phenethylamine compounds.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 CAD | +11.89% | +1.91% | -24.53% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.53% | 4.69M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- DRUG Stock
- News Bright Minds Biosciences Inc.
- Bright Minds Biosciences Inc. Receives Favorable Written Opinion from the International Searching Authority for BMB-202